References
- Herdeiro MT, Ferreira M, Ribeiro-Vaz I, et al. [The Portuguese Pharmacovigilance System]. Acta Med Port 2012;25:241–9.
- Crijns I, Mantel-Teeuwisse A, Bloemberg R, et al. Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study. Expert Opin Drug Saf 2013;12:29–8.
- Prieto L, Spooner A, Hidalgo-Simon A, et al. Evaluation of the effectiveness of risk minimization measures. Pharmacoepidemiol Drug Saf 2012;21:896–9.
- Blackburn S, Arlett P. Benefit Risk Management Plans? Pharm Med 2013;27:5–8.
- EMA. Guideline on good pharmacovigilance practices (GVP) Module V- Risk management systems (Rev 1), 25 April 2014. London: European Medicines Agency and Heads of Medicines Agencies; 2014.
- Zuniga L, Calvo B. Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf 2010;19:661–9.
- Frau S, Font Pous M, Luppino MR, et al. Risk Management Plans: are they a tool for improving drug safety? Eur J Clin Pharmacol 2010;66:785–90.
- Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010. Available online at: http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/FARMACOVIGILANCIA/NOVA_LEGISLACAO_FARMACOVIGILANCIA/Directiva_2010_84_15_12_2010.pdf. Accessed April 2013.
- Regulamento (UE) N.° 1235/2010 do Parlamento Europeu e do Conselho, de 15 de Dezembro 2010. Available online at: http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/FARMACOVIGILANCIA/NOVA_LEGISLACAO_FARMACOVIGILANCIA/Regulamento_1235_2010_15_12_2010.pdf. Accessed April 2013.
- Commission Implementing Regulation (EU) N. 520/2012 of 19 june 2012. OJEU; 2012. Available online at: http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/FARMACOVIGILANCIA/NOVA_LEGISLACAO_FARMACOVIGILANCIA/PT_Regulamento%20de%20Execucao_520_2012_19_06_2012.pdf. Accessed May 2013.
- Autret-Leca E, Kreft-Jais C, Elefant E, et al. Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France. Drug Saf 2010;33:659–65.
- Shin J, Cheetham TC, Wong L, et al. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system. J Am Acad Dermatol 2011;65:1117–25.
- Crijns HJ, Straus SM, Gispen-de Wied C, et al. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Br J Dermatol 2011;164:238–44.
- Zomerdijk IM, Trifiro G, Sayed-Tabatabaei FA, et al. Additional risk minimisation measures in the EU - are they eligible for assessment? Pharmacoepidemiol Drug Saf 2013;22:1046–53.
- Urushihara H, Kobashi G, Masuda H, et al. Pharmaceutical company perspectives on current safety risk communications in Japan. Springerplus 2014;3:51.
- Bahri P, Harrison-Woolrych M. How to improve communication for the safe use of medicines?: discussions on social marketing and patient-tailored approaches at the annual meetings of the WHO Programme for International Drug Monitoring. Drug Saf 2012;35:1073–9.
- Bahri P. Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies. Drug Saf 2010;33:1065–79.
- Robson C. Real World Research: a Resource for Social Scientists and Practitioner-Researchers. Oxford, UK, Blackwell Publishers Lda; 1993.
- Gavaza P, Brown CM, Lawson KA, et al. Texas pharmacists' knowledge of reporting serious adverse drug events to the Food and Drug Administration. J Am Pharm Assoc (2003) 2011;51:397–403.
- Vala J, MB M. Psicologia social. 9th ed. Lisboa: Fundação Calouste Gulbenkian; 2013.
- Andrews E, Dombeck M. The role of scientific evidence of risks and benefits in determining risk management policies for medications. Pharmacoepidemiol Drug Saf 2004;13:599–608.
- Bahri P, Harrison-Woolrych M. Focusing on risk communication about medicines: why now? Drug Saf 2012;35:971–5.
- Wallman A, Vaudan C, Sporrong SK. Communications training in pharmacy education, 1995-2010. Am J Pharm Educ 2013;77:36.
- Mesquita AR, Lyra DP, Brito GC, et al. Developing communication skills in pharmacy: a systematic review of the use of simulated patient methods. Patient Educ Couns 2010;78:143–8.
- Smith MP, Webley SD. Pharmacovigilance teaching in UK undergraduate pharmacy programmes. Pharmacoepidemiol Drug Saf 2013;22:223–8.
- Elkalmi RM, Hassali MA, Ibrahim MI, et al. Pharmacy students' knowledge and perceptions about pharmacovigilance in Malaysian public universities. Am J Pharm Educ 2011;75:96.
- Piening S, Haaijer-Ruskamp FM, de Graeff PA, et al. Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands. Drug Saf 2012;35:1061–72.